Results 101 to 110 of about 149 (135)
Journal of Clinical Psychology, Volume 81, Issue 6, Page 434-444, June 2025.ABSTRACT Objective There is increasing interest in the impact of endometriosis on body image, however, there is minimal understanding of the presence and nature of disordered eating. As body image dissatisfaction is elevated in this population and a risk factor for eating disorders, it is likely that disordered eating is also elevated which has ...
Mia L. Pellizzer +2 more
wiley +1 more source
Erythema Nodosum in Hidradenitis Suppurativa: A Case Series
JEADV Clinical Practice, Volume 4, Issue 2, Page 532-534, June 2025.Capsule SummaryHidradenitis suppurativa (HS) is a chronic inflammatory condition linked to dermatologic and multisystem comorbidities. While associations with immunological and inflammatory conditions are less frequently reported, erythema nodosum (EN) has been shown to occur.
Katie K. Lovell +3 more
wiley +1 more source
Maternal stress and fetoplacental cortisol regulation in small‐for‐gestational‐age newborns
Ultrasound in Obstetrics &Gynecology, Volume 65, Issue 6, Page 738-748, June 2025.ABSTRACT Objective Previous research has identified an association between maternal stress, fetal growth and the expression of glucocorticoid‐related genes in the placenta, particularly 11‐beta hydroxysteroid dehydrogenase‐2 (HSD11β2). However, to date, no studies have simultaneously explored the relationships between maternal stress, placental ...
J. Miranda +11 more
wiley +1 more source
BJOG: An International Journal of Obstetrics &Gynaecology, Volume 132, Issue 7, Page 991-999, June 2025.ABSTRACT Objective Undergoing medically assisted reproduction (MAR) has been linked to mixed mental health outcomes in women. We investigated the risk of postpartum depression (PPD) among mothers conceiving with MAR compared to mothers conceiving spontaneously. Design Register‐Based Study. Setting Denmark.
Sofie Egsgaard +5 more
wiley +1 more source
Risk Factors for Adverse Pregnancy Outcomes in Reduced Fetal Movement: An IPD Meta‐Analysis
BJOG: An International Journal of Obstetrics &Gynaecology, Volume 132, Issue 7, Page 1000-1009, June 2025.ABSTRACT Objective Women experiencing reduced fetal movements (RFM) have an increased risk of adverse pregnancy outcomes (APO). This study aimed to identify factors most associated with APO in RFM pregnancies. Design Individual participant data meta‐analysis (IPD‐MA). Setting Multiple maternity units across the UK.
Yongyi Lu +2 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue 6, Page 3185-3194, June 2025.Abstract Aims To understand real‐world tirzepatide use among individuals without type 2 diabetes (T2D) diagnoses in a US electronic health record (EHR) database. Materials and Methods This retrospective, descriptive, cohort study used Veradigm's® Network EHR database linked with administrative claims.
Theresa Hunter Gibble +7 more
wiley +1 more source
A narrative review of metformin in pregnancy: Navigating benefit and uncertainty
Diabetes, Obesity and Metabolism, Volume 27, Issue S3, Page 16-30, June 2025.Abstract Metformin is well‐established as a treatment for type 2 diabetes in non‐pregnant individuals. The low cost, acceptability and broad tolerability of metformin have also made it an attractive option for research into the treatment of other conditions associated with insulin resistance.
Robert P. McEvoy +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue S3, Page 48-63, June 2025.Abstract Metformin is widely prescribed for the management of type 2 diabetes mellitus, polycystic ovary syndrome, and gestational diabetes mellitus in pregnancy. Its use is driven by factors including oral administration, lower patient and health system burden and cost, and benefits including lower risk of excess gestational weight gain and ...
Tharaka Mayadunne +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue S3, Page 31-47, June 2025.Abstract Metformin, a synthetic biguanide, is widely used to manage type 2 diabetes, and is commonly prescribed in polycystic ovary syndrome (PCOS) to address insulin resistance and associated metabolic and reproductive disturbances. PCOS is characterised by hormonal imbalances such as hyperandrogenism and anovulation, metabolic abnormalities including
Saeede Saadati +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 27, Issue S3, Page 3-15, June 2025.Abstract The prevalence of prediabetes has more than doubled over the past two decades. Although hormones associated with the menstrual cycle may offer some protection against diabetes by enhancing insulin sensitivity and suppressing gluconeogenesis, the prevalence of diabetes among women remains high at 10.5%.
Beth Shi Yu Lim +3 more
wiley +1 more source